Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of November 2013. The report announces a significant corporate development regarding the listing of the Company's American Depository Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory and listing updates rather than financial performance data.
Material Changes
- Exchange Listing: The Company's ADRs were approved for listing on the NYSE MKT.
- Trading Transition: Trading is expected to commence on the NYSE MKT on November 19, 2013, under the ticker symbol "CANF".
- Previous Trading Venue: Prior to the NYSE MKT listing, ADRs traded on the U.S. Over-the-Counter Markets (OTCQB: CANFY).
- Regulatory Filing: A Form 8-A was filed to register the ADRs and underlying ordinary shares (par value NIS 0.25) pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The document serves strictly to disclose the listing approval and the associated Form 8-A filing.
Investor Verification Checklist
- Confirm the commencement of trading on the NYSE MKT under ticker "CANF" on November 19, 2013.
- Verify the transition of trading volume from the OTCQB market to the NYSE MKT.
- Review the attached Form 8-A (Exhibit 99.2) for details on the registered share capital and ADR structure.
- Check subsequent filings for the first financial results following the exchange listing.